The Week in Review #44
Quarterly Financial Results
What Was Seen and What Was Ignored
History and self-experiences enabled investors to expect and swallow biased reactions following the announcements of the biotech sector’s firms’ quarterly results. Investors have long been expecting negative reactions towards small development-stage biotech firms following the announcement of their quarterly financial results. What they did not expect is for the same negative reactions against the best accomplishing and scientifically performing giant biotech firms.
After years of sales of breakthrough products, investors usually expect the revenues of these drugs to decrease as their patents . . .